Several contributions challenge the assumption that CKD is a single, homogeneous entity once glomerular filtration rate and albuminuria are known. Romano and colleagues revisit Bricker’s decades-old intact nephron hypothesis, which holds that surviving nephrons compensate for lost ones by hyperfiltering, and propose a complementary hypofiltering nephron model in which structurally intact nephrons filter less because of increased preglomerular vascular resistance and hypoperfusion rather than nephron loss per se. Because current KDIGO staging relies solely on estimated GFR and albuminuria categories, the authors argue that mechanistically distinct patients are too often treated identically. They propose that renal hemodynamic markers, such as the intrarenal Doppler-derived resistive index, could help personalize management, and they claim that patients with CKD and hypofiltering residual nephrons should be treated differently than those with hyperfiltration of residual nephrons. This conceptual work is complemented by Rico-Fontalvo and colleagues, whose mini review dissects how obesity drives CKD through interlinked inflammatory and lipotoxic pathways, reinforcing that metabolic phenotype, not eGFR alone, shapes disease trajectory. The authors discuss their proposed classification of obesity-related CKD.

Pregnancy offers a further illustration of why reliance on non-pregnant laboratory norms can misclassify abnormalities and delay recognition of clinically important disturbances. Meena and Batool synthesize how systemic vasodilation, neurohormonal activation, and maternal-fetal mineral exchange reset the normal ranges for osmoregulation, sodium-water homeostasis, potassium, magnesium, and calcium across gestation. Their synthesis provides a practical framework for distinguishing physiological adaptation from pathological disturbance in this understudied area of obstetric nephrology, a distinction with direct consequences for how clinicians interpret routine blood tests in pregnant patients and decide when an abnormal value reflects genuine disease rather than expected gestational change.

Two original research articles test therapies aimed at the outcomes that matter most to patients with CKD: kidney failure and cardiovascular disease. Aledan and Abbood report a prospective cohort study of finerenone in 180 patients with CKD stages 3 to 4, with estimated GFR between 20 and 60 mL/min, including diabetic and non-diabetic participants and patients with eGFR as low as 20 mL/min, populations historically underrepresented in finerenone trials. Over one year, finerenone significantly improved eGFR and urinary albumin-to-creatinine ratio without a meaningful rise in serum potassium, extending the evidence base for this drug class to a broader, more advanced CKD population. The nonsteroidal mineralocorticoid receptor antagonist class has drawn intense attention since large outcome trials, and this real-world cohort adds weight to the argument that patients with more advanced disease can also benefit when monitoring protocols are followed.

Cardiovascular risk after transplantation is the focus of Thuy and Thang’s study of plasma asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, in 75 patients before and six months after kidney transplantation. ADMA fell substantially after transplant but remained more than three times higher than in healthy controls, and was independently associated with dyslipidemia, the atherogenic index of plasma, and post-transplant hemoglobin and HDL-cholesterol levels. The findings support ADMA as a candidate marker of residual cardiovascular risk even after otherwise successful transplantation, a clinically important point because cardiovascular disease remains a leading cause of death with a functioning graft, and because conventional risk scores often fail to capture the specific metabolic and inflammatory milieu of transplant recipients.

A number of papers explore how biomarkers and computational methods can enhance and sharpen diagnosis. Fu and colleagues review neutrophil gelatinase-associated lipocalin, known as NGAL, as a biomarker for both acute kidney injury and peritoneal dialysis-related peritonitis, arguing for its potential as an early, non-invasive signal across two clinically distinct but mechanistically related complications. Wu and colleagues use the electronic Intensive Care Unit Collaborative Research Database to examine the association between serum bicarbonate and 28-day in-hospital mortality in dialysis patients, adding evidence that acid-base status carries prognostic weight in critically ill patients on renal replacement therapy. Their research indicates that serum bicarbonate levels below 30 mmol/L are linked to an increased risk of death. Jiang and colleagues apply machine learning to transcriptomic data to build and validate a diagnostic model linking two chronic wasting diseases, uremia and major depressive disorder, and begin to map the shared molecular biology behind a common but under-recognized comorbidity of kidney failure. In the transplantation space, Loizeau and colleagues quantify measurement uncertainty in renal transplant biopsy assessment, a reminder that even the histopathologic gold standard for diagnosing rejection carries inter-observer variability that should inform treatment decisions.

Two contributions bring the discussion back to the patient. Shankar and Lamech catalog the treatment burden imposed by long-term immunosuppressive therapy for glomerular disease, weighing efficacy against infection risk, metabolic complications, and quality of life, financial burden, and calling for strategies judged not only by remission rates but by what patients endure to achieve them. Qi and colleagues contribute a case report of IgA nephropathy with partial crescentic lesions in a patient with brucellosis, an unusual juxtaposition that highlights how systemic infection can unmask or accelerate glomerular injury. Crescentic lesions signal aggressive inflammation within the glomeruli, and the association with a chronic bacterial infection raises questions about whether immune activation driven by the pathogen contributed to the renal lesion, a mechanism that remains speculative but clinically instructive for nephrologists evaluating patients with concurrent infection and rapidly progressive kidney disease.

Across these eleven articles, several threads recur despite the breadth of topics. The limits of GFR and albuminuria as the sole means for staging CKD emerge repeatedly, whether through the hypofiltering nephron model, the metabolic classification of obesity-related kidney disease, or the hemodynamic markers proposed to refine risk assessment. The persistence of cardiovascular risk even after kidney replacement appears both in the finerenone cohort and in the ADMA study, underscoring that restoring kidney function does not automatically restore vascular health. The value of biomarkers that anticipate injury rather than merely confirm it runs through the NGAL review, the bicarbonate mortality analysis, and the transcriptomic modeling of uremic depression, while the transplant biopsy uncertainty study adds a cautionary note about the reliability of the diagnostic gold standard itself.

The human cost of therapies used to control glomerular disease completes the picture. Immunosuppressive regimens have transformed once-fatal glomerulopathies into manageable conditions, yet the catalog of infections, metabolic complications, financial strain, and quality-of-life sacrifices documented by Shankar and Lamech argues for a broader definition of treatment success. In parallel, the obstetric nephrology synthesis and the brucellosis-associated IgA nephropathy case remind readers that kidney disease does not occur in isolation from pregnancy physiology or systemic infection, and that context-specific norms and mechanisms are essential for accurate diagnosis.

That breadth is precisely the point of a Rising Stars collection: it captures the range of questions that early-career nephrologists are choosing to ask, from nephron-level physiology to population-scale database analyses, from pharmacologic trials to bioinformatic modeling of comorbidity. The editorial’s author thanks the authors, reviewers, and editors who contributed to the Research Topic, and looks forward to seeing how these emerging investigators continue to shape the future of kidney health. For a field confronting a global epidemic of kidney disease, the message is that the pipeline of ideas, methods, and investigators is active, technically diverse, and already producing evidence that could change how CKD is staged, how cardiovascular risk is measured after transplantation, and how the burden of treatment is weighed against its benefits.

Subject of Research: Early-career nephrology research spanning CKD staging, biomarkers, transplantation, and glomerular disease

Article Title: Editorial: Rising stars in nephrology 2024: illuminating the future of kidney health

Article References: Kotanko, P. (2026). Editorial: Rising stars in nephrology 2024: illuminating the future of kidney health. Frontiers in Nephrology, 6, Article 1985175. https://doi.org/10.3389/fneph.2026.1985175

Image Credits: AI Generated

DOI: 10.3389/fneph.2026.1985175

Keywords: chronic kidney disease, nephrology, finerenone, kidney transplantation, biomarkers, NGAL, ADMA, machine learning, pregnancy, glomerular disease, dialysis, immunosuppression